Asthma and pulmonary arterial hypertension: Do they share a key mechanism of pathogenesis?

European Respiratory Journal

Volumn 35, Issue 4, 2010, Pages 730-734

  Said, S I ^a,b   Hamidi, S A ^a,b   Bosc, L Gonzalez ^c  

^a STONY BROOK UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma; Pulmonary hypertension; Remodelling; Transcription factor

Indexed keywords

CALCINEURIN; TRANSCRIPTION FACTOR NFAT; VASOACTIVE INTESTINAL POLYPEPTIDE;

AIRWAY CONSTRICTION; AIRWAY INFLAMMATION; ASTHMA; CELL PROLIFERATION; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

ASTHMA; CALCINEURIN; HUMANS; HYPERTENSION, PULMONARY; MUSCLE, SMOOTH, VASCULAR; NFATC TRANSCRIPTION FACTORS; PNEUMONIA; PULMONARY ARTERY; SIGNAL TRANSDUCTION;

EID: 77951154552     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00097109     Document Type: Review

References (52)

1. Bousquet J, Jeffery PK, Busse WW, et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720-1745. (Pubitemid 30329053)
2. Benayoun L, Druilhe A, Dombret MC, et al. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003; 167: 1360-1368. (Pubitemid 36609720)
3. Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004; 22: 789-815. (Pubitemid 38680442)
4. Pascual RM, Peters SP. Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol 2005; 116: 477-486.
5. Boulet LP, Sterk PJ. Airway remodelling: the future. Eur Respir J 2007; 30: 831-834.
6. Mauad T, Bel EH, Sterk PJ. Asthma therapy and airway remodeling. J Allergy Clin Immunol 2007; 120: 997-1009.
7. Broide DH. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol 2008; 121: 560-570.
8. Ray A, Cohn L. Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. J Clin Invest 1999; 104: 985-993. (Pubitemid 29536304)
9. Dorfmüller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-363.
10. Oka M, Homma N, Taraseviciene-Stewart L, et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007; 100: 923-929. (Pubitemid 46555698)
11. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8: 2129-2138.
12. Rabinovitch M. Pathobiology of pulmonary hypertension. Annu Rev Pathol 2007; 2: 369-399.
13. Salmon M, Walsh DA, Koto H, et al. Repeated allergen exposure of sensitized Brown-Norway rats induces airway cell DNA synthesis and remodelling. Eur Respir J 1999; 14: 633-641. (Pubitemid 29479731)
14. Henderson WR Jr, Tang LO, Chu SJ, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002; 165: 108-116. (Pubitemid 34053366)
15. Leigh R, Ellis R, Wattie J, et al. Dysfunction and remodeling of the mouse airway persist after resolution of acute allergen-induced airway inflammation. Am J Respir Cell Mol Biol 2002; 27: 526-535. (Pubitemid 35301806)
16. Woodruff PG, Dolganov GM, Ferrando RE, et al. Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. Am J Respir Crit Care Med 2004; 169: 1001-1006.
17. Homer RJ, Elias JA. Airway remodeling in asthma: therapeutic implications of mechanisms. Physiology (Bethesda) 2005; 20: 28-35. (Pubitemid 40363368)
18. McMillan SJ, Xanthou G, Lloyd CM. Manipulation of allergeninduced airway remodeling by treatment with anti-TGF-b antibody: effect on the Smad signaling pathway. J Immunol 2005; 174: 5774-5780. (Pubitemid 40593221)
19. Henderson WR Jr, Chiang GK, Tien YT, et al. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006; 173: 718-728.
20. Lloyd CM, Robinson DS. Allergen-induced airway remodelling. Eur Respir J 2007; 29: 1020-1032.
21. Elias JA, Zhu Z, Chupp G, et al. Airway remodeling in asthma. J Clin Invest 1999; 104: 1001-1006.
22. Panettieri RA Jr. Cellular and molecular mechanisms regulating airway smooth muscle proliferation and cell adhesion molecule expression. Am J Respir Crit Care Med 1998; 158: S133-S140.
23. Fahy JV, Corry DB, Boushey HA. Airway inflammation and remodeling in asthma. Curr Opin Pulm Med 2000; 6: 15-20.
24. Ammit AJ, Panettieri RA Jr. Airway smooth muscle cell hyperplasia: a therapeutic target in airway remodeling in asthma? Prog Cell Cycle Res 2003; 5: 49-57.
25. Fixman ED, Stewart A, Martin JG. Basic mechanisms of development of airway structural changes in asthma. Eur Respir J 2007; 29: 379-389. (Pubitemid 46231919)
26. Kiani A, Rao A, Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 2000; 12: 359-372.
27. Diehl S, Krahl T, Rinaldi L, et al. Inhibition of NFAT specifically in T cells prevents allergic pulmonary inflammation. J Immunol 2004; 172: 3597-3603. (Pubitemid 38337941)
28. Monticelli S, Solymar DC, Rao A. Role of NFAT proteins in IL13 gene transcription in mast cells. J Biol Chem 2004; 279: 36210-36218. (Pubitemid 39128956)
29. Nakamura Y, Yamauchi K, Inoue H. Novel ribbon-Type NF-AT decoy oligodeoxynucleotides preclude Th2 cytokines expression and airways hyperreactivity in experimental asthma. J Allergy Clin Immunol 2006; 117: S245-S245.
30. de Frutos S, Spangler R, Alo D, et al. NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with alpha-actin up-regulation. J Biol Chem 2007; 282: 15081-15089. (Pubitemid 47093376)
31. Koulmann N, Novel-Chate V, Peinnequin A, et al. Cyclosporin A inhibits hypoxia-induced pulmonary hypertension and right ventricle hypertrophy. Am J Respir Crit Care Med 2006; 174: 699-705. (Pubitemid 44395338)
32. Bonnet S, Rochefort G, Sutendra G, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 2007; 104: 11418-11423. (Pubitemid 47175155)
33. Said SI, Hamidi SA, Dickman KG, et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 2007; 115: 1260-1268. (Pubitemid 46594770)
34. Szema AM, Hamidi SA, Lyubsky S, et al. Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol 2006; 291: L880-L886. (Pubitemid 44772049)
35. Daley E, Emson C, Guignabert C, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 2008; 205: 361-372. (Pubitemid 351281602)
36. Rydell-Törmänen K, Uller L, Persson CG, et al. Allergen exposure of mouse airways evokes remodeling of both bronchi and large pulmonary vessels. Am J Respir Crit Care Med 2005; 171: 19-25. (Pubitemid 40051690)
37. Rydell-Törmänen K, Uller L, Erjefä lt JS. Remodeling of extrabronchial lung vasculature following allergic airway inflammation. Respir Res 2008; 9: 18.
38. Rydell-Törmänen K, Johnson JR, Fattouh R, et al. Induction of vascular remodeling in the lung by chronic house dust mite exposure. Am J Respir Cell Mol Biol 2008; 39: 61-67. (Pubitemid 351883959)
39. Persson CG, Erjfä lt JS, Korsgren M, et al. The mouse trap. Trends Pharmacol Sci 1997; 18: 465-467.
40. Saetta M, Di Stefano A, Rosina C, et al. Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma. Am Rev Respir Dis 1991; 143: 138-143.
41. Green FH, Butt JC, James AL, et al. Abnormalities of the bronchial arteries in asthma. Chest 2006; 130: 1025-1033.
42. Badri KR, Zhou Y, Schuger L. Embryological origin of airway smooth muscle. Proc Am Thorac Soc 2008; 5: 4-10.
43. Wang Z, Shu W, Lu MM, et al. Wnt7b activates canonical signaling in epithelial and vascular smooth muscle cells through interactions with Fzd1, Fzd10, and LRP5. Mol Cell Biol 2005; 25: 5022-5030. (Pubitemid 40781102)
44. Gosens R, Meurs H, Schmidt M. The GSK-3/beta-catenin-signalling axis in smooth muscle and its relationship with remodelling. Naunyn Schmiedebergs Arch Pharmacol 2008; 378: 185-191. (Pubitemid 351977640)
45. Loscertales M, Mikels AJ, Hu JK, et al. Chick pulmonary Wnt5a directs airway and vascular tubulogenesis. Development 2008; 135: 1365-1376. (Pubitemid 351622480)
46. Nunes RO, Schmidt M, Dueck G, et al. GSK-3/beta-catenin signaling axis in airway smooth muscle: role in mitogenic signaling. Am J Physiol Lung Cell Mol Physiol 2008; 294: L1110-1118.
47. Bentley JK, Deng H, Linn MJ, et al. Airway smooth muscle hyperplasia and hypertrophy correlate with glycogen synthase kinase-3(beta) phosphorylation in a mouse model of asthma. Am J Physiol Lung Cell Mol Physiol 2009; 296: L176-L184.
48. Fernandes DJ, McConville JF, Stewart AG, et al. Can we differentiate between airway and vascular smooth muscle? Clin Exp Pharmacol Physiol 2004; 31: 805-810.
49. Aramburu J, Yaffe MB, Lopez-Rodriguez C, et al. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 1999; 285: 2129-2133.
50. Said SI. The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation. Ann NY Acad Sci 2008; 1144: 148-153.
51. Said SI. Vasoactive intestinal polypeptide (VIP) in asthma. Ann NY Acad Sci 1991; 629: 305-318.
52. Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111: 1339-1346.